Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101842 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
A Phase 1 study of Carcinoma, Transitional Cell, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT00101842: Completed Phase 1 study of Carcinoma, Transitional Cell, sponsored by Eli Lilly and Company.
NCT00101842 is a Phase 1 study of Carcinoma, Transitional Cell that has completed, run by Eli Lilly and Company. The registered enrollment target is 61 participants, below the 298-participant average among 5 other Carcinoma, Transitional Cell trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00101842, a Phase 1 study of Carcinoma, Transitional Cell, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To determine the safety of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine and any side effects that might be associated with the combination of these drugs; To determine whether Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine can help patients with advanced bladder cancer live longer; To determine whether Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine can make your tumor smaller or disappear, and for how long.
Conditions Studied
Interventions
- DRUG Pemetrexed
- DRUG Gemcitabine
- DRUG Platinol
Study Locations (1)
Texas
- For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-07 |
| Phase | Phase 1 |
What the finished NCT00101842 record still lists
NCT00101842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 298-participant average among 5 other Carcinoma, Transitional Cell trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Carcinoma, Transitional Cell appearing as the primary indexed condition, and to 3 interventions - of which Pemetrexed is the first listed.
NCT00101842 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00101842 about?
NCT00101842 is a clinical study titled "Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer". The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To determine the safety of Gemcitabine and Platinol followed by Pemetrexed...
What is the current status of trial NCT00101842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2004-12. Estimated completion is 2006-07.
What conditions does trial NCT00101842 study?
This clinical trial studies the following conditions: Carcinoma, Transitional Cell.
What interventions are being tested in trial NCT00101842?
The interventions under investigation include: Pemetrexed (DRUG), Gemcitabine (DRUG), Platinol (DRUG).
Who is sponsoring clinical trial NCT00101842?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00101842 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Transitional Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 1
-
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RECRUITING
-
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RECRUITING · Phase 3
-
The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
COMPLETED · Phase 3
-
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia